Ftse Mib
34.780,81
1,91%
DAX
20.216,19
1,54%
S&P 500
5.975,38
0,55%
NASDAQ
19.864,98
1,24%
Bitcoin
101.812,43
-0,46%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Regno Unito LSE Pharma Equity Group A/s (0REU) Pharma Equity Group A/s (0REU) Notizie

0REU

Pharma Equity Group A/s (0REU)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0REU
DataOraFonteTitoloSimboloCompagnia
13/12/202412:21UK RegulatoryThe Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.LSE:0REUPharma Equity Group A/s
29/11/202407:45UK RegulatoryMartin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
15/11/202408:32UK RegulatoryConsolidated Interim report 1 January – 30 September 2024LSE:0REUPharma Equity Group A/s
23/10/202410:28UK RegulatoryPharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.LSE:0REUPharma Equity Group A/s
14/10/202408:17UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
14/10/202407:59UK RegulatoryManagers’ transactions LSE:0REUPharma Equity Group A/s
11/10/202408:37UK RegulatoryPharma Equity Group announces successful completion of directed issue of new sharesLSE:0REUPharma Equity Group A/s
04/10/202413:52UK RegulatoryPharma Equity Group announces issuance of new shares in a direct issueLSE:0REUPharma Equity Group A/s
04/10/202409:01UK RegulatoryRegistration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rightsLSE:0REUPharma Equity Group A/s
16/08/202408:52UK RegulatoryConsolidated Interim Report 1 January – 30 June 2024LSE:0REUPharma Equity Group A/s
16/07/202410:09UK RegulatoryThe Board of Directors' decision to issue convertible loansLSE:0REUPharma Equity Group A/s
03/06/202416:17UK RegulatoryResults of extraordinary general meeting in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
16/05/202412:35UK RegulatoryThe Board of Director's decision to issue convertible loansLSE:0REUPharma Equity Group A/s
16/05/202407:27UK RegulatoryConsolidated interim report 1 January – 31 March 2024LSE:0REUPharma Equity Group A/s
08/05/202415:16UK RegulatoryExploration of options regarding a directed capital increase at market price in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
08/05/202410:20UK RegulatoryNotice convening the extraordinary general meeting of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
16/04/202417:29UK RegulatoryPassing of the General Meeting of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
05/04/202411:22UK RegulatoryPharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.LSE:0REUPharma Equity Group A/s
25/03/202413:06UK RegulatoryNotice convening the annual general meeting in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
22/03/202409:00UK RegulatoryPharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009LSE:0REUPharma Equity Group A/s
21/03/202416:32UK RegulatoryCompletion of subscription of convertible loansLSE:0REUPharma Equity Group A/s
20/03/202408:58UK RegulatoryPharma Equity Group A/S - Annual Report 2023LSE:0REUPharma Equity Group A/s
05/03/202410:11UK RegulatoryPharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).LSE:0REUPharma Equity Group A/s
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0REU

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
STMMI
ST Microelectronics
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
CPR
Davide Campari
BIT
LDO
Leonardo
BIT
SPM
Saipem
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
IVG
Iveco Group NV
BIT
BPE
Bper Banca
BIT
MONC
Moncler
BIT
AMP
Amplifon
BIT
TIT
Telecom Italia
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network